Health

mRNA Cancer Vaccine Succeeds in Late-Stage Melanoma Trial

Is this a genuine medical breakthrough or a dangerous financial gamble built on shattered trust?

Published 1 day ago

mRNA Cancer Vaccine Succeeds in Late-Stage Melanoma Trial

story

Above: An assistant conducts cancer vaccine research in a lab at Moderna Inc.'s headquarters in Cambridge, Massachusetts, on March 26, 2024. Image credit: Adam Glanzman/Bloomberg/Getty Images

The Spin

Pro-establishment narrative

The first positive Phase 3 trial of a personalized mRNA cancer vaccine is a genuine landmark — not hype, but hard clinical evidence from over 1,100 patients showing real reductions in recurrence for high-risk melanoma. Designing a treatment around each tumor's unique mutations was once a dream, and now it's reality. 2026 deserves to be remembered as the year mRNA technology proved its most consequential promise had nothing to do with COVID-19.

Dr. Catharine Young on X

Toni Choueiri, MD on X

Adam Feuerstein on X

Establishment-critical narrative

Moderna's mRNA cancer vaccine is just the latest chapter in a troubling pattern — the same controversial technology behind COVID-19 shots that triggered myocarditis warnings and global political firestorms is now being repackaged as a cancer cure. The stock pumping 90% on Phase 3 news smells more like financial engineering than a medical miracle. Trust in mRNA was shattered once, and rushing to rebuild it on the back of cancer patients is a dangerous gamble.

ColonelTowner-Watkins on X

StarPlatinum on X

Metaculus Prediction

There's a 50% chance that there will be a breakthrough in the treatment of hard-to-treat cancers by Oct. 29, 2030, according to the Metaculus prediction community.